BioNTech SE (BNTX) Tops Q2 EPS by EUR1.86
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioNTech Announces Second Quarter 2021 Financial Results and Corporate Update
August 9, 2021 7:00 AM EDTMore than one billion doses of BNT162b2 vaccine supplied to more than 100 countries or territories worldwide as of July 21, 2021Signed agreements for approximately 2.2 billion doses of BNT162b2 in 2021 as of July 21, 2021In oncology, the first patients were dosed in randomized Phase 2 trials for two FixVac programs, BNT111 and BNT113, and first-in-human Phase 1 trials started for BNT152+153 and BNT221BioNTechs oncology pipeline has advanced: currently 15 product candidates in 18 ongoing trials
Conference call and webcast scheduled for August 9, 2021, at 8:00 a.m. ET (2:00 p.m. CET)
MAINZ,... More
